NDA 216318 · Azurity
Azmiro
Testosterone Cypionate · Intramuscular
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jun 2, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
8 Phase 3, 11 recruiting
FAERS reports
5,970
2,795 serious, 193 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 25, 2025.
AZMIRO is indicated for testosterone replacement therapy in males in conditions associated with a deficiency or absence of endogenous testosterone: • Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchiectomy, Klinefelter’s syndrome, or toxic damage from alcohol or heavy metals, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range [ see Dosage and Administration ( 2.2 ) ]. • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range [ see Dosage and Administration (2.2) ]. Limitations of Use • Safety and efficacy of AZMIRO in men with “age- related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. • Safety and efficacy of AZMIRO in pediatric patients below the age of 12 years have not been established [ see Use in Specific Populations ( 8.4 ) ]. AZMIRO is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ): Limitations of Use: • Safety and efficacy of AZMIRO in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established ( 1 ). • Safety and effectiveness in pediatric patients below the age of 12 years have not been established ( 8.4 ).
Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AZMIRO · TESTOSTERONE CYPIONATE 200MG/ML (200MG/ML) · SOLUTION, INTRAMUSCULAR · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Testosterone Cypionate" as an intervention, any sponsor and status, largest first.
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerPivotal-lookingNot yet recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT07852195 · 432 participants (planned) · Start Jan 6, 2027 · Primary completion Mar 31, 2029
Drug: Abiraterone Acetate; Cabazitaxel and 8 more · For: Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismPivotal-lookingCompleted
Lipocine Inc.Industry
NCT02081300 · 315 participants · Start Feb 2014 · Primary completion May 2015
Drug: Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 % · For: Male Hypogonadism
- Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI TrialPivotal-lookingNot yet recruiting
VA Office of Research and DevelopmentFederal agency
NCT07742553 · 300 participants (planned) · Start Oct 1, 2027 · Primary completion Sep 30, 2031
Drug: testosterone cypionate; finasteride and 2 more · For: Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord and 11 more
Sites: Aurora, Colorado; Gainesville, Florida; Tampa, Florida · 4 sites in all
- Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistancePivotal-lookingCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT02286921 · 222 participants · Start Jan 2015 · Primary completion Oct 26, 2018
Drug: Testosterone cypionate; Enzalutamide and 1 more · For: Castration Resistant Metastatic Prostate Cancer
Sites: Birmingham, Alabama; Duarte, California; Aurora, Colorado · 17 sites in all
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismPivotal-lookingRecruiting
Amneal Pharmaceuticals, LLCIndustry
NCT07898072 · 190 participants (planned) · Start Sep 28, 2026 · Primary completion Mar 31, 2027
Drug: Testosterone Cypionate 75 mg; Testosterone cypionate 50 mg and 1 more · For: Male Hypogonadism
Sites: Santa Monica, California; DeLand, Florida; Miami Lakes, Florida · 10 sites in all
- Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionPivotal-lookingRecruiting
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT04363164 · 150 participants (planned) · Start Aug 19, 2020 · Primary completion Jul 2027
Drug: Testosterone cypionate; Enzalutamide and 1 more · For: Castration Resistant Metastatic Prostate Cancer
Sites: San Diego, California; Baltimore, Maryland; Boston, Massachusetts · 6 sites in all
- Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal MenNot yet recruiting
Azurity PharmaceuticalsIndustry
NCT07328542 · 144 participants (planned) · Start Feb 2026 · Primary completion Jun 2027
Drug: Testosterone Cypionate Injection 200 mg/mL · For: Hypogonadism, Male
Sites: Birmingham, Alabama; DeLand, Florida; Hialeah, Florida · 6 sites in all
- Improving Quality of Life of Prostate Cancer Survivors With Androgen DeficiencyPivotal-lookingCompleted
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03716739 · 136 participants · Start Mar 19, 2019 · Primary completion May 16, 2025
Drug: Testosterone Cypionate 100 MG/ML; Placebo · For: Prostate Cancer
Sites: Baltimore, Maryland; Boston, Massachusetts · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective437
- product dose omission issue384
- fatigue369
- off label use286
- product deposit273
- pain248
- liquid product physical issue247
- injection site pain240
- poor quality product administered217
- headache199
- myocardial infarction187
- nausea184
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 21 |
| 2010 | 18 |
| 2011 | 27 |
| 2012 | 39 |
| 2013 | 42 |
| 2014 | 110 |
| 2015 | 283 |
| 2016 | 648 |
| 2017 | 315 |
| 2018 | 423 |
| 2019 | 388 |
| 2020 | 444 |
| 2021 | 378 |
| 2022 | 396 |
| 2023 | 477 |
| 2024 | 580 |
| 2025 | 841 |
| 2026 | 516 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.
Bhasin S, Burnett AL, Gagliano-Jucá T, et al. · JAMA Intern Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
Sena LA, Wang H, Lim ScM SJ, et al. · Eur J Cancer 2021 · Clinical Trial, Phase II, Multicenter Study
- Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study.
Okano SHP, Franceschini SA, Cantelli DAL, et al. · J Sex Med 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC, Taplin ME, Aggarwal R, et al. · Nat Commun 2024 · Clinical Trial, Phase II, Multicenter Study
- The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials.
Nackeeran S, Kohn T, Gonzalez D, et al. · J Urol 2022 · Comparative Study, Systematic Review
- Transient reduction in serum HDL-cholesterol following medroxyprogesterone acetate and testosterone cypionate administration to healthy men.
Friedl KE, Plymate SR, Paulsen CA · Contraception 1985 · Clinical Trial, Randomized Controlled Trial
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.